Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Smoking and Brain Derived Neurotrophic Factor (BDNF) Levels in Serum


Affiliations
1 Departments of Forensic Medicine and Clinical Toxicology and Clinical Pathology Mansoura Faculty of Medicine, Egypt
     

   Subscribe/Renew Journal


Brain derived neurotrophic factor (BDNF) is a member of neurotrophins which are a family of proteins whose action
influence neurons of the central nervous system. The aim of the present study is to compare the differences in serum
BDNF level in smokers and non-smokers to better clarify the relationship between smoking and BDNF. The BDNF is
measured in 88 subjects chosen randomly (33 non-smokers and 55 smokers). All subjects are free from any chronic
physical disease, allergy, psychiatric disorders and regular medications. A self-made questionnaire is given to each subject
stating the age, amount of cigarette use (no. of cigarette / day), age of the first use and duration of use. Body mass index
are calculated. In addition, Fagerstrom test for nicotine dependence (FTND) and smoking index are calculated. The
results reveal no significant difference between BDNF level in smokers and non-smokers. It is concluded that although
BDNF level in the present study does not show any significant difference between smokers and non-smokers, this
relationship needs further researches to be established and future studies will need to recruit more subjects in order to
increase the statistical power of the research.

Keywords

Neurotrophines, BDNF, Smoking, Nicotine, Drug of Abuse
Subscription Login to verify subscription
User
Notifications
Font Size


  • Balkowiec, A and Katz, DM (1998). "Brain-derived neurotrophic factor is required for normal development of the central respiratory rhythm in mice". J. Physiol 510: 527-533.
  • Barakat-Walter, I (1996). "Brain-derived neurotrophic factor-like immunoreactivity is localized mainly in small sensory neurons of rat dorsal root ganglia". J. Neuro Sci, Methods 68(2): 281-288.
  • Bertaux, O, Toselli-Mollereau, E, Auffray, C, et al. (2004). "Alternative usage of five exons in the chicken nerve growth factor gene: Refined characterization of a weakly expressed gene". Gene 334:83-97.
  • Bhang, SY, Choi, SW and Ahn, JH (2010). "Changes in plasma brain derived neurotrophic factor levels in smokers after smoking cessation". Neuroscience Letters 468:7-11.
  • Buckley, PF, Mahadik, S, Pillai, A, et al. (2007). "Neurotrophins and schizophrenia". Schizophrenia Research 94:1-11.
  • Chao, MV, Rajagopal, R and Lee, FS (2006). "Neurotrophin signalling in health and disease." Clin Sci, 110: 167-173.
  • Fujimura, H, Altar, CA, Chen, R, Nakamura, T, Nakahashi, T, Kambayashi, J, Sun, B and Tabdon, NN (2002). "Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation". Thromb Haemost 87: 728-734.
  • Goldstein, RZ and Volkow, ND (2002). "Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex". Am. J. Psychiatry, 159:1642- 1652.
  • Groves, JO (2007). "Is it time to reassess the BDNF hypothesis of depression"? Mol. Psychiatry 12: 1079-1088.
  • Hatsukami, DK, Stead, LF and Gupta, PC (2008). "Tobacco addiction". Lancet 371:2027-2038.
  • Heatherton, TF (1991). "The Fagerström test for nicotine dependence: A revision of the Fagerström tolerance questionnaire". British Journal of Addiction 86:1119-1127.
  • Horger, BA, Iyasere, CA, Berhow, MT, Messer, CJ, Nestler, EJ, and Taylor, JR, (1999). "Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor". J. Neurosci 19: 4110-4122.
  • Huang, EJ and Reichardt, LF (2001). "Neurotrophins: Roles in neuronal development and function". Annu. Rev. Neurosci., 2:677-786.
  • Kenny, PJ, File, SE and Rattray, M (2000). "Acute nicotine decreases and chronic nicotine increases the expression of brainderived neurotrophic factor mRNA in rat hippocampus". Brain Res. Mol. Brain Res 85: 234-238.
  • Kim, TS, Kim, DJ, Lee, H, et al. (2007). "Increased plasma brain derived neurotrophic factor levels in chronic smokers following unaided smoking cessation". Neuroscience Letters 423:53-57.
  • Kokaia, Z, Nawa, H, Uchino, H, Elmer, E and Kokaia, M (1996). "Regional brain-derived neurotrophic factor mRNA and protein levels following transient forebrain ischemia in the rat". Brain Res. Mol. Brain Res 38(1): 139-144.
  • Matsubara, F, Kida, M, Tamakoshi, A, Wakai, K, Kawamura, T and Ohno, Y (2002). "Maternal active and passive smoking and fetal growth: A prospective study in Nagoya, Japan". J. Epidemiol, 10: 335-343.
  • Pan, W, Banks, WA, Fasold, MB, Bluth, J and Kastin, A J (1998). "Transport of brain-derived neurotrophic factor across the bloodbrain barrier." Neuropsychopharmacology 37: 1553-1561.
  • Thomas, MJ, Kalivas, PW and Shaham, Y (2008). "Neuroplasticity in the mesolimbic dopamine system and cocaine addiction." Br. J. Pharmacol 154: 327-342.
  • Yeom, M, Shim, I, Lee, HJ and Hahm, DH (2005). "Proteomic analysis of nicotine associated protein expression in the striatum of repeated nicotine-treated rats". Biochem. Biophys. Res. Commun 326: 321-328.
  • Zhang, XY, Xiu, MH, Chen, DC, De Yang, F, Wu, GY, Lu, L, Kosten, TA and Kosten, TR (2010). "Nicotine dependence and serum BDNF levels in male patients with schizophrenia". Psychopharmacology (Berl).

Abstract Views: 346

PDF Views: 3




  • Smoking and Brain Derived Neurotrophic Factor (BDNF) Levels in Serum

Abstract Views: 346  |  PDF Views: 3

Authors

Amany Ragab Yousef
Departments of Forensic Medicine and Clinical Toxicology and Clinical Pathology Mansoura Faculty of Medicine, Egypt

Abstract


Brain derived neurotrophic factor (BDNF) is a member of neurotrophins which are a family of proteins whose action
influence neurons of the central nervous system. The aim of the present study is to compare the differences in serum
BDNF level in smokers and non-smokers to better clarify the relationship between smoking and BDNF. The BDNF is
measured in 88 subjects chosen randomly (33 non-smokers and 55 smokers). All subjects are free from any chronic
physical disease, allergy, psychiatric disorders and regular medications. A self-made questionnaire is given to each subject
stating the age, amount of cigarette use (no. of cigarette / day), age of the first use and duration of use. Body mass index
are calculated. In addition, Fagerstrom test for nicotine dependence (FTND) and smoking index are calculated. The
results reveal no significant difference between BDNF level in smokers and non-smokers. It is concluded that although
BDNF level in the present study does not show any significant difference between smokers and non-smokers, this
relationship needs further researches to be established and future studies will need to recruit more subjects in order to
increase the statistical power of the research.

Keywords


Neurotrophines, BDNF, Smoking, Nicotine, Drug of Abuse

References